In percutaneous coronary intervention (PCI), the concept of securing metal free angioplasty without leaving behind a permanent foreign body is highly attractive to patients and physicians and promises several advantages. However, target lesion failure and device thrombosis were important concerns with first-generation Bioresorbable scaffolds (BRS) leading to low rates of adoption in clinical practice (1-12). New iterations, incorporating improvements such as a smaller strut thickness have been proposed and evaluated in early investigations. However, it remains unclear whether these modifications are sufficient to achieve outcomes comparable to those of metallic drug-eluting stents (DES) while preserving the benefits of resorption (10-12).
Authors Heartbeat Sub-Editor: Sandeep Singh Dr Sandeep Singh is a Cardiology Clinical Fellow at Nottingham University Hospitals NHS Trust. After graduating from India, he completed
Authors Heartbeat Sub-Editor: Khin Kay Kay Kyaw I am currently working as cardiology specialist registrar ST6 at southwest peninsula region while also working as an
Authors Heartbeat Sub-Editor: Anindya Mukherjee Dr. Anindya Mukherjee is a ST5 trainee registrar in Cardiology at Mid Yorkshire Teaching NHS Trust, UK, with extensive experience
Authors Sub-editor: Sameer Zaman Heartbeat Sub-Editor: Aleena Haider Aleena is an academic cardiology trainee at Imperial College London with a strong commitment to all aspects
Authors Sub-editor: Sameer Zaman Heartbeat Sub-Editor: Padraig O Drisceoil Dr Pádraig Ó Drisceoil is a Cardiology Speciality Trainee from the Wessex Deanery, who is currently an
